Michael Zinke1, Vanasa Nageswaran1, Richard Reinhardt2, Thomas Burmeister3,4. 1. Charité, Med. Klinik für Hämatologie, Onkologie, Tumorimmunologie, Hindenburgdamm 30, 12200, Berlin, Germany. 2. Max-Planck-Genomzentrum, Cologne, Germany. 3. Charité, Med. Klinik für Hämatologie, Onkologie, Tumorimmunologie, Hindenburgdamm 30, 12200, Berlin, Germany. thomas.burmeister@charite.de. 4. Labor Berlin, Hematology-Tumor Genetics, Berlin, Germany. thomas.burmeister@charite.de.
Abstract
BACKGROUND: The majority of patients with JAK2 V617F-negative essential thrombocythemia or primary myelofibrosis harbor mutations involving the calreticulin (CALR) gene. These mutations are located in CALR exon 9 and lead to a frameshift with subsequent alteration of the CALR protein C-terminus. They have emerged as valuable molecular markers for the diagnosis of clonal myeloproliferative diseases. Although a variety of CALR mutations have been described, two mutations, denoted type 1 and type 2, account for around 85 % of cases. The type 1 mutation encompasses a 52 bp deletion and the type 2 mutation a 5 bp TTGTC insertion. METHODS: This work describes the development and testing of quantitative real-time PCRs (qPCRs) for detecting these two mutations. RESULTS: The final type 1 CALR qPCR displayed a sensitivity of <0.1 % mutant alleles and the type 2 CALR qPCR had a sensitivity of <0.01 % mutant alleles. Additionally, two new CALR mutations are reported. CONCLUSION: These sensitive and specific qPCRs should be helpful in establishing the diagnosis and in monitoring minimal residual disease in patients during or after therapy.
BACKGROUND: The majority of patients with JAK2 V617F-negative essential thrombocythemia or primary myelofibrosis harbor mutations involving the calreticulin (CALR) gene. These mutations are located in CALR exon 9 and lead to a frameshift with subsequent alteration of the CALR protein C-terminus. They have emerged as valuable molecular markers for the diagnosis of clonal myeloproliferative diseases. Although a variety of CALR mutations have been described, two mutations, denoted type 1 and type 2, account for around 85 % of cases. The type 1 mutation encompasses a 52 bp deletion and the type 2 mutation a 5 bp TTGTC insertion. METHODS: This work describes the development and testing of quantitative real-time PCRs (qPCRs) for detecting these two mutations. RESULTS: The final type 1 CALR qPCR displayed a sensitivity of <0.1 % mutant alleles and the type 2 CALR qPCR had a sensitivity of <0.01 % mutant alleles. Additionally, two new CALR mutations are reported. CONCLUSION: These sensitive and specific qPCRs should be helpful in establishing the diagnosis and in monitoring minimal residual disease in patients during or after therapy.
Authors: V H J van der Velden; A Hochhaus; G Cazzaniga; T Szczepanski; J Gabert; J J M van Dongen Journal: Leukemia Date: 2003-06 Impact factor: 11.528
Authors: Amy V Jones; Daniel Ward; Matthew Lyon; William Leung; Alison Callaway; Andrew Chase; Carolyn L Dent; Helen E White; Hans G Drexler; Jyoti Nangalia; Chris Mattocks; Nicholas C P Cross Journal: Leuk Res Date: 2014-11-29 Impact factor: 3.156
Authors: A Tefferi; T L Lasho; C Finke; A A Belachew; E A Wassie; R P Ketterling; C A Hanson; A Pardanani Journal: Leukemia Date: 2014-02-26 Impact factor: 11.528
Authors: T Burmeister; R Marschalek; B Schneider; C Meyer; N Gökbuget; S Schwartz; D Hoelzer; E Thiel Journal: Leukemia Date: 2006-03 Impact factor: 11.528
Authors: Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics Journal: N Engl J Med Date: 2013-12-10 Impact factor: 91.245
Authors: Ngo Tat Trung; Dao Thanh Quyen; Nghiem Xuan Hoan; Dao Phuong Giang; Tran Thi Huyen Trang; Thirumalaisamy P Velavan; Mai Hong Bang; Le Huu Song Journal: BMC Med Genet Date: 2019-06-27 Impact factor: 2.103